At a glance
ClinicalIndex Comparison RecordN/ACompleted· 123 enrolled
Drug / intervention
SU011248drug
Likely dose
SU011248 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
In Brief
A clinical study evaluating SU011248 for Neoplasms. Completed, enrolled 123 participants across 62 sites in 7 countries.
Detailed Summary
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesCanada, France, Germany, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMar 2007
Primary CompletionDec 2011
TodayJul 2026
First PostedMar 6, 2007
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 19.3 years ago
Interventions
SU011248drug
Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol